SCHEMBL4091312

SCHEMBL4091312

COCCNC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2c1CCCC2

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 11/20 0.77
CNR1 P21554 3/20 0.77
ALDH1A1 P00352 4/20 0.61
MAPT P10636 4/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
KDM4E B2RXH2 3/20 0.61
HPGD P15428 2/20 0.61
THRB P10828 2/20 0.61
HSD17B10 Q99714 2/20 0.61
MEN1 O00255 1/20 0.61
ALOX15 P16050 1/20 0.61
KMT2A Q03164 1/20 0.61
CYP1A2 P05177 2/20 0.56
CYP2C9 P11712 2/20 0.56
CYP3A4 P08684 1/20 0.55
CYP2C19 P33261 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
PSMD14 O00487 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089814 0.94 CNR2 (0.67) CNR2CNR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL4084217 0.90 CNR2 (0.63) CNR2CNR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL4084167 0.89 CNR2 (0.74) CNR2CNR1ALDH1A1MEN1KMT2A
SCHEMBL4090251 0.89 CNR2 (0.62) CNR2CNR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL4079868 0.87 CNR2 (0.66) CNR2CNR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL4095565 0.86 CNR2 (0.74) CNR2CNR1KDM4EKMT2ACYP1A2
SCHEMBL4085782 0.86 CYP1A2 (0.71) CNR2CNR1ALDH1A1MAPTKDM4E
SCHEMBL4086068 0.86 CNR2 (0.81) CNR2CNR1
SCHEMBL4090539 0.86 CNR2 (0.59) CNR2CNR1ALDH1A1MAPTKDM4E
SCHEMBL4080819 0.86 KMT2A (0.60) CNR2CNR1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885CNR1 1/4885ALDH1A1 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.